Literature DB >> 10595976

The influence of regional spinal cord hypothermia on transcranial myogenic motor-evoked potential monitoring and the efficacy of spinal cord ischemia detection.

S A Meylaerts1, P De Haan, C J Kalkman, J Lips, B A De Mol, M J Jacobs.   

Abstract

OBJECTIVE: Myogenic motor-evoked responses to transcranial electrical stimulation (transcranial myogenic motor-evoked potentials) can rapidly detect spinal cord ischemia during thoracoabdominal aortic aneurysm repair. Recent evidence suggests that regional spinal cord hypothermia increases spinal cord ischemia tolerance. We investigated the influence of subdural infusion cooling on transcranial myogenic motor-evoked potential characteristics and the time to detect spinal cord ischemia in 6 pigs.
METHODS: Regional hypothermia was produced by subdural perfusion cooling. A laminectomy and incision of the dura were performed at L2 to advance 2 inflow catheters at L4 and L6, to cool the lumbar subdural space with saline solution. Two temperature probes were advanced at L3 and L5, and 1 cerebrospinal fluid pressure line was advanced at L4. Spontaneous cerebrospinal fluid outflow was allowed. Spinal cord ischemia was produced by clamping a set of critical lumbar arteries, previously identified by transcranial myogenic motor-evoked potentials and lumbar artery clamping. The time between the onset of ischemia and detection with transcranial myogenic motor-evoked potentials (amplitude < 25%) was determined at cerebrospinal fluid temperatures of 37 degrees C and 28 degrees C. Thereafter, the influence of progressive cerebrospinal fluid cooling on transcranial myogenic motor-evoked potential amplitude and latency was determined.
RESULTS: The time necessary to produce ischemic transcranial myogenic motor-evoked potentials, after the clamping of critical lumbar arteries, was not affected at moderate subdural hypothermia (3.8 +/- 0.9 min) compared with subdural normothermia (3.2 +/- 0.5 min; P =.6). Thereafter, progressive cooling resulted in a transcranial myogenic motor-evoked potential amplitude increase at 28 degrees C to 30 degrees C and was followed by a progressive decrease. Response amplitudes decreased below 25% at 14.0 degrees C +/- 1.1 degrees C. The influence of cerebrospinal fluid temperature on transcranial myogenic motor-evoked potential amplitude was best represented by a quadratic regression curve with a maximum at 29.6 degrees C. In contrast, transcranial myogenic motor-evoked potential latencies increased linearly with decreasing subdural temperatures.
CONCLUSIONS: Detection of spinal cord ischemia with transcranial myogenic motor-evoked potentials is not delayed at moderate subdural hypothermia in pigs. At a cerebrospinal fluid temperature of 28 degrees C, transcranial myogenic motor-evoked potential amplitudes are increased. Further cerebrospinal fluid temperature decreases result in progressive amplitude decreases and latency increases.

Entities:  

Mesh:

Year:  1999        PMID: 10595976     DOI: 10.1016/S0022-5223(99)70099-1

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

1.  Influence of electrode impedance on threshold voltage for transcranial electrical stimulation in motor evoked potential monitoring.

Authors:  H L Journée; H E Polak; M de Kleuver
Journal:  Med Biol Eng Comput       Date:  2004-07       Impact factor: 2.602

2.  Improvement of motor evoked potentials monitoring is required during thoracic or thoracoabdominal aortic aneurysm surgery under hypothermic cardiopulmonary bypass.

Authors:  Masahiko Kawaguchi; Mikito Kawamata; Yoshitsugu Yamada
Journal:  J Anesth       Date:  2012-02-23       Impact factor: 2.078

3.  Changes of motor evoked potentials during descending thoracic and thoracoabdominal aortic surgery with deep hypothermic circulatory arrest.

Authors:  Masahide Shinzawa; Kenji Yoshitani; Kenji Minatoya; Tomoya Irie; Hitoshi Ogino; Yoshihiko Ohnishi
Journal:  J Anesth       Date:  2011-12-27       Impact factor: 2.078

Review 4.  A practical guide for anesthetic management during intraoperative motor evoked potential monitoring.

Authors:  Masahiko Kawaguchi; Hiroki Iida; Satoshi Tanaka; Naokazu Fukuoka; Hironobu Hayashi; Shunsuke Izumi; Kenji Yoshitani; Manabu Kakinohana
Journal:  J Anesth       Date:  2019-10-19       Impact factor: 2.078

5.  Comparison of carbamylated erythropoietin-FC fusion protein and recombinant human erythropoietin during porcine aortic balloon occlusion-induced spinal cord ischemia/reperfusion injury.

Authors:  Florian Simon; Angelika Scheuerle; Michael Gröger; Brigitta Vcelar; Oscar McCook; Peter Möller; Michael Georgieff; Enrico Calzia; Peter Radermacher; Hubert Schelzig
Journal:  Intensive Care Med       Date:  2011-07-16       Impact factor: 17.440

6.  Prolonged loss of leg myogenic motor evoked potentials during thoracoabdominal aortic aneurysm repair, without postoperative paraplegia.

Authors:  Sadahei Denda; Miki Taneoka; Hiroyuki Honda; Yukiko Watanabe; Hidekazu Imai; Yasushi Kitahara
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

7.  A Case of Decreased Amplitude in Motor Evoked Potentials Under Remimazolam Anesthesia.

Authors:  Yuichi Aratani; Yasuyuki Tokinaga; Tadashi Tanioku; Tomoyuki Maruyama; Tomoyuki Kawamata
Journal:  Cureus       Date:  2022-08-02

8.  Multipulse transcranial electrical stimulation (TES): normative data for motor evoked potentials in healthy horses.

Authors:  Sanne Lotte Journée; Henricus Louis Journée; Cornelis Marinus de Bruijn; Cathérine John Ghislaine Delesalle
Journal:  BMC Vet Res       Date:  2018-04-03       Impact factor: 2.741

9.  Intravenous hydrogen sulfide does not induce neuroprotection after aortic balloon occlusion-induced spinal cord ischemia/reperfusion injury in a human-like porcine model of ubiquitous arteriosclerosis.

Authors:  Andre Bredthauer; Karla Lehle; Angelika Scheuerle; Hubert Schelzig; Oscar McCook; Peter Radermacher; Csaba Szabo; Martin Wepler; Florian Simon
Journal:  Intensive Care Med Exp       Date:  2018-10-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.